Search clinical trials for: Aromatase Inhibitor and Palbociclib

Total 63716 results

Pfizer

Completed

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)

Metastatic Breast Cancer

Spain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
Pfizer

Completed

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Metastatic Breast Cancer

United States
Pfizer

Completed

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Metastatic Breast Cancer

United States
Pfizer

Active, not recruiting

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Metastatic Breast Cancer

United States
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Breast Neoplasms

Qatar, United Arab Emirates, Saudi Arabia
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PREDIX LumB)

Early-Stage Breast Carcinoma | Estrogen Receptor Positive Tumor

Sweden
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (CAPACITY)

Hormone Receptor Positive Advanced Breast Cancer

China
International Cancer Research Group, United Arab...
King Saud University Medical City, Riyadh, Saudi Arabia; Max-Planck-Institut... and other collaborators

Recruiting

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (ICRG0201)

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Algeria, Jordan, Saudi Arabia
Canadian Cancer Trials Group
Pfizer

Completed

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer

Canada
Nordic Society of Gynaecological Oncology - Clinical...
European Network of Gynaecological Oncological Trial Groups (ENGOT); Grupo... and other collaborators

Completed

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Endometrial Cancer

Denmark
NSABP Foundation Inc
Royal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...

Completed

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (PALLET)

Breast Cancer | Breast Tumors | Breast Carcinoma

United Kingdom, United States, Canada
Sudipto Mukherjee

Active, not recruiting

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML

United States
Pfizer

Completed

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Breast Cancer

Japan
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Shengjing Hospital

Recruiting

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Breast Cancer

China
Pfizer

Completed

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Breast Neoplasms

Spain, Korea, Republic of, United States, Australia, Italy, Russian Federation
MedSIR
Pfizer

Completed

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (DxCARTES)

Breast Cancer

Spain, Portugal
Borstkanker Onderzoek Groep

Active, not recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female

Netherlands
Latin American Cooperative Oncology Group
Pfizer

Completed

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (LACOG1018)

Ovarian Cancer

Brazil
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Pfizer

Completed

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

Healthy

United States
Tvardi Therapeutics, Incorporated

Active, not recruiting

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)

Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

Sweden
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Megalabs

Not yet recruiting

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

Bioequivalence
Pfizer

Completed

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

Healthy

United States
Pfizer

Active, not recruiting

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
Pfizer

Completed

Relative Bioavailability For Palbociclib Formulations

Healthy

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Sarcoma | Liposarcoma

United States
University of Colorado, Denver
Pfizer; Criterium, Inc.; Cascadian Therapeutics Inc.

Completed

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Breast Cancer

United States
Pfizer

Completed

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Healthy

United States
Weill Medical College of Cornell University

Recruiting

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Breast Cancer

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Pfizer

Completed

A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

Healthy

United States
Massachusetts General Hospital
Genentech, Inc.

Active, not recruiting

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Breast Cancer

United States
Weill Medical College of Cornell University

Withdrawn

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)

Breast Cancer
Pfizer

Completed

Study Of Palbociclib (PD-0332991) In Renal Impairment

Renal Impairment

United States
University of Kansas Medical Center
Pfizer

Terminated

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

HER2-positive Breast Cancer | Breast Cancer Metastatic

United States
Georgetown University
University of Chicago; Thomas Jefferson University

Completed

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (PALINA)

Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Pfizer

Recruiting

Swedish Ibrance Registries Insights (SIRI) (SIRI)

Malignant Neoplasm of Breast

Sweden
Pfizer

Completed

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Metastatic Breast Cancer

Israel
Pfizer

Completed

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

Healthy

United States
InventisBio Co., Ltd

Completed

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States, China
Pfizer

Active, not recruiting

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Advanced Breast Cancer

China
Pfizer

No longer available

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Advanced Breast Cancer (Female)

Canada, United States
University of Nebraska

Recruiting

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Breast Cancer

United States
Pfizer

Recruiting

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (PERFORM)

Breast Neoplasms

Austria, Germany
Royal Marsden NHS Foundation Trust
Pfizer; Roche Pharma AG; Institute of Cancer Research, United Kingdom

Unknown

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)

Breast Cancer | Advanced Solid Tumours

United Kingdom
Pfizer

Completed

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

Hormone Receptor Positive Advanced Breast Cancer

China

3

Subscribe